Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High‐Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE)

OBJECTIVES:The assessment of cancer risk in patients with Barrett's esophagus (BE) is currently fraught with difficulty. The current gold standard method of assessing cancer risk is histological assessment, with the appearance of high-grade dysplasia (HGD) as the key event monitored. Sampling error during endoscopy limits the usefulness of this approach, and there has been much recent interest in supplementing histological assessment with molecular markers, which may aid in patient stratification.METHODS:No molecular marker has been yet validated to accurately correlate with esophageal histological progression. Here, we assessed the suitability of several membranous proteins as biomarkers by correlating their abundance with histological progression. In all, 107 patient samples, from 100 patients, were arranged on a tissue microarray (TMA) and represented the various stages of histological progression in BE. This TMA was probed with antibodies for eight receptor proteins (mostly membranous).RESULTS:Epidermal growth factor receptor (EGFR) staining was found to be the most promising biomarker identified with clear increases in staining accompanying histological progression. Further, immunohistochemistry was performed using the full-tissue sections from BE, HGD, and adenocarcinoma tissues, which confirmed the stepwise increase in EGFR abundance. Using a robust H-score analysis, EGFR abundance was shown to increase 13-fold in the adenocarcinoma tissues compared to the BE tissues. EGFR was “overexpressed” in 35% of HGD specimens and 80% of adenocarcinoma specimens when using the H-score of the BE patients (plus 3 s.d.) as the threshold to define overexpression. EGFR staining was also noted to be higher in BE tissues adjacent to HGD/adenocarcinoma. Western blotting, although showing more EGFR protein in the adenocarcinomas compared to the BE tissue, was highly variable. EGFR overexpression was accompanied by aneuploidy (gain) of chromosome 7, plus amplification of the EGFR locus. Finally, the bile acid deoxycholic acid (DCA) (at neutral and acidic pH) and acid alone was capable of upregulating EGFR mRNA in vitro, and in the case of neutral pH DCA, this was NF-κB dependent.CONCLUSIONS:EGFR is overexpressed during the histological progression in BE tissues and hence may be useful as a biomarker of histological progression. Furthermore, as EGFR is a membranous protein expressed on the luminal surface of the esophageal mucosa, it may also be a useful target for biopsy guidance during endoscopy.

[1]  P. Hainaut,et al.  p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. , 2005, Cancer letters.

[2]  H. Sasano,et al.  Immunohistochemical Studies on EGF Family Growth Factors in Normal and Ulcerated Human Gastric Mucosa , 1997, Digestive Diseases and Sciences.

[3]  N. Shaheen,et al.  Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[5]  T. Junginger,et al.  Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis , 1998, Cancer.

[6]  D. Wakelin,et al.  Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.

[7]  C. Reed,et al.  Tumor marker expression is predictive of survival in patients with esophageal cancer. , 2001, The Annals of thoracic surgery.

[8]  Kenneth K Wang,et al.  Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia–Dysplasia–Adenocarcinoma Sequence of Barrett's Esophagus , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[10]  P. V. van Diest,et al.  Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas , 2006, Journal of Clinical Pathology.

[11]  N. Quenville,et al.  Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67 , 1992, Journal of surgical oncology.

[12]  Joseph Schlessinger,et al.  Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.

[13]  H. Smart,et al.  Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.

[14]  J. Black,et al.  Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma , 2004, Journal of Gastrointestinal Surgery.

[15]  Janusz Jankowski,et al.  Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas , 2006, Clinical Cancer Research.

[16]  Tsung-Teh Wu,et al.  Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  N. Sergina,et al.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets. , 2007, Trends in molecular medicine.

[18]  H. Ludwig,et al.  The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.

[19]  P. Altevogt,et al.  Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease‐dependent ectodomain shedding and exosome secretion , 2008, Journal of cellular biochemistry.

[20]  N. Shepherd,et al.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. , 1995, Journal of clinical pathology.

[21]  Markus F Neurath,et al.  Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy , 2010, Gut.

[22]  J. Reynolds,et al.  NF-&kgr;B Activation in Esophageal Adenocarcinoma: Relationship to Barrett's Metaplasia, Survival, and Response to Neoadjuvant Chemoradiotherapy , 2004, Annals of surgery.

[23]  N. Shepherd,et al.  c-erbB2 overexpression in the dysplasia / carcinoma sequence of Barrett ' s oesophagus , 2022 .

[24]  D. Beer,et al.  Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.

[25]  R. Cade,et al.  Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett's oesophagus , 2003, ANZ journal of surgery.

[26]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[27]  D. Forman,et al.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[28]  G. Tytgat,et al.  Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma , 1998, Gut.

[29]  J. Ajani,et al.  Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas , 2007, Cancer.

[30]  Patricia L. Blount,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .

[31]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[32]  J. Black,et al.  Epidermal Growth Factor Receptor-Directed Therapy in Esophageal Cancer , 2008, Oncology.

[33]  D. Forman,et al.  TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort , 2006, Gut.

[34]  J R Siewert,et al.  Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. , 2000, The American journal of pathology.

[35]  Edward L. Lee,et al.  In situ hybridization for the detection of telomerase RNA in the progression from barrett's esophagus to esophageal adenocarcinoma , 1998, Cancer.

[36]  W. Hop,et al.  Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. , 2008, American journal of clinical pathology.

[37]  D. Ferry,et al.  A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response , 2007, Clinical Cancer Research.

[38]  G. Lyratzopoulos,et al.  Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. , 2009, Gastroenterology.

[39]  R. Langer,et al.  Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study , 2006, Journal of Clinical Pathology.

[40]  P. Groeneveld,et al.  Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.